The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype
about
Preclinical validation of interleukin 6 as a therapeutic target in multiple myelomaDHP-derivative and low oxygen tension effectively induces human adipose stromal cell reprogrammingDifferentiation stage of myeloma plasma cells: biological and clinical significance.Advances in the understanding of myeloma bone disease and tumour growth.Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell linesTargeting bone as a therapy for myeloma.Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivoProgress in myeloma stem cellsPrimary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.Evolution of adaptive phenotypic traits without positive Darwinian selection.Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaNAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.Transcription factors that regulate memory in humoral responses.Role of decorin in the antimyeloma effects of osteoblasts.The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.Anti-CD20 monoclonal antibody therapy in multiple myeloma.Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts.Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance.Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells.Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.Induced cancer stem cells generated by radiochemotherapy and their therapeutic implications.Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.Wnt signaling in leukemias and myeloma: T-cell factors are in control.Concise review: Defining and targeting myeloma stem cell-like cells.Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis.Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsKLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models.Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort.Nestin expression throughout multistep pathogenesis of multiple myeloma.A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis
P2860
Q27027729-4997B8F6-1BEE-4958-B205-A889A81BC0EFQ28472822-6992CC4C-5A05-4A6C-AE53-66A10ACA394BQ33712516-A40A2A22-CDA7-470F-94C1-CCA1753582EAQ33829022-F0128D77-A698-4EA2-B64F-B516232B5450Q34418934-259E200A-1BA0-4924-BDEE-AE3CD33008BEQ34448984-B25F34D7-426A-4189-95F2-2966A143614AQ35128148-DB18BFC5-0259-4B0C-82DC-A294BACF2335Q35603128-5765F5B1-5388-408B-9DEB-76AEE585090FQ35642745-6ED0B8AE-427E-4ECC-91CC-F9886698A427Q35824980-C4214235-260C-44B3-B9E6-B03E7A10F1F5Q35834665-4C4D3D1D-E10A-4D23-ABC4-69DD0D2895B5Q35854956-8DE9C59D-56D3-4039-9747-2D2608B152C2Q36284584-876EBD0D-D221-460F-ABA1-8A565BF8D81BQ36288116-14024434-9153-4ED8-BDF1-F278091161D2Q36529017-3064A533-29F9-4E3D-9DD8-5D11F4D6FCE4Q36732801-7EFC6B6D-7A40-40BD-92C7-3DB7048FE3FEQ37034189-80B06FA7-877B-49CA-8513-57AE5B939A1EQ37101674-A9E7959E-206E-412E-B3A6-2AE160F9AE62Q37344577-002F1161-E232-400A-AB43-E1A2779A14B9Q37357836-35A72E0A-B816-4163-8A50-03054EC02D0CQ37407676-EFA5F14D-E0A0-40F8-B4C1-6C7F59D247DCQ37452148-35D1DB5F-41B9-4C55-8E43-A7068828A1C9Q37535244-DA967A5A-8CDE-476C-AC43-823AF969599CQ37684348-7C0C1E64-5999-4DD0-B2B6-107BBC503DC0Q37725612-60912F2C-C85A-4B3B-ACEE-973F8214EA91Q38151195-5BC476D5-F639-493B-82EA-8F26AE305F6FQ38155205-A380A501-CD4F-4FFC-B795-573E8A9B1493Q38180656-DA8038E6-3E51-49FF-A8B9-1E86EA7D45E1Q38778519-1DAE9837-0C71-48A8-AB48-2D25CE410955Q38789282-7A2DBB96-459E-4802-832E-BD23DB0E6820Q38860336-5F389AC7-40A3-470E-90DC-A3ACA673C40EQ39078376-78539EFF-F551-4524-8BF8-180639BF20A7Q40760595-20A3D93B-0D53-4CE1-A8DE-F70EBFA8039EQ50703544-33C704FE-1AA7-479C-AB17-4DBF6DAC04B0Q58698408-C4D8A0CB-CA69-4484-8B29-8784EA9597D0
P2860
The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The phenotypic plasticity of m ...... apoptosis-resistant phenotype
@ast
The phenotypic plasticity of m ...... apoptosis-resistant phenotype
@en
type
label
The phenotypic plasticity of m ...... apoptosis-resistant phenotype
@ast
The phenotypic plasticity of m ...... apoptosis-resistant phenotype
@en
prefLabel
The phenotypic plasticity of m ...... apoptosis-resistant phenotype
@ast
The phenotypic plasticity of m ...... apoptosis-resistant phenotype
@en
P2860
P1476
The phenotypic plasticity of m ...... apoptosis-resistant phenotype
@en
P2860
P304
P356
10.1158/1078-0432.CCR-05-0523
P407
P577
2005-11-01T00:00:00Z